Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

283P - Effect of study-level factors on treatment-free remission rate in patients with chronic myeloid leukemia: A systematic review and meta-analysis

Date

23 Nov 2019

Session

Poster display session

Topics

Tumour Site

Leukaemias

Presenters

Jinhyun Cho

Citation

Annals of Oncology (2019) 30 (suppl_9): ix91-ix96. 10.1093/annonc/mdz427

Authors

J. Cho, J. Kim, J. Park, J.H. Lim, M.H. Lee

Author affiliations

  • Hematology-oncology, Inha University Hospital, 22332 - Incheon/KR

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 283P

Background

As most assessments for treatment-free remission (TFR) in patients with chronic myeloid leukemia are recommended to be conducted as prospective trials, we conducted a systematic review and meta-analysis to investigate which study-level factors affected the TFR rate.

Methods

The MEDLINE, Embase, and Cochrane databases were systematically searched from inception to July 2018. A random effect model was used to estimate the overall mean TFR rate, subgroup differences, and regression coefficients with continuous variables.

Results

Overall, 12 tyrosine kinase inhibitor (TKI) stopping studies comprising 1,699 chronic myeloid leukemia patients were included in the analyses. The overall mean TFR rate at 24 months after entering TFR phase was 55% (95% confidence interval [CI], 0.51–0.58). Trials with molecular criteria of MR4.5 or better for stopping TKI reported higher TFR rates than those of MR4.0 (57.2% vs. 50.5%). Trials with eligible criteria for at least 24 months of deep molecular response (DMR) duration demonstrated higher TFR rates than those for 18 or 12 months (60.2% vs. 49.9%).

Conclusions

It is expected that TKI stopping trials with sufficient duration of DMR and molecular criteria of MR4.5 or better could secure approximately 60% of the TFR rate at 24 months after stopping TKI.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.